每周给予氟尿嘧啶和顺铂同步放化疗治疗局部晚期头颈部癌症患者。

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Head Neck. 2010 Feb;32(2):235-43. doi: 10.1002/hed.21177.

DOI:10.1002/hed.21177

PMID:19572288

Abstract

BACKGROUND

In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival. Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU-cisplatin in locally advanced head and neck cancer.

METHODS

In a single-arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5-FU (750 mg/m2) and cisplatin (20 mg/m2).

RESULTS

Thirty-two patients completed planned radiation. Thirteen (41%) achieved complete response, and 16 (50%) partial response. Twelve patients (38%) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16%) patients. The survival rates at 1 and 2 years were 81% and 76%, respectively. The progression-free survival rates at 1 and 2 years were 69% and 66%, respectively.

CONCLUSIONS

We demonstrated weekly 5-FU-cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer.

摘要

背景

在局部晚期头颈部癌症中，联合应用氟尿嘧啶（5-FU）和顺铂的同期放化疗（CRT）增加了急性毒性和生存率。每周一次的化疗给药方案可能会降低严重毒性。因此，我们研究了每周给予氟尿嘧啶-顺铂的 CRT 在局部晚期头颈部癌症中的应用。

方法

在一项单臂、Ⅱ期研究中，CRT 包括放疗（70.0 Gy/35 次）和每周氟尿嘧啶（750 mg/m2）和顺铂（20 mg/m2）。

结果

32 例患者完成了计划的放疗。13 例（41%）达到完全缓解，16 例（50%）部分缓解。12 例（38%）患者出现急性 3 级毒性。最常见的毒性是 3 级黏膜炎，发生在 5 例（16%）患者中。1 年和 2 年的生存率分别为 81%和 76%。1 年和 2 年的无进展生存率分别为 69%和 66%。